JP4370168B2 - プロピオニルl−カルニチンまたはその医薬上許容される塩の1つのペイロニー病の治療用医薬の調製のための使用 - Google Patents
プロピオニルl−カルニチンまたはその医薬上許容される塩の1つのペイロニー病の治療用医薬の調製のための使用 Download PDFInfo
- Publication number
- JP4370168B2 JP4370168B2 JP2003546875A JP2003546875A JP4370168B2 JP 4370168 B2 JP4370168 B2 JP 4370168B2 JP 2003546875 A JP2003546875 A JP 2003546875A JP 2003546875 A JP2003546875 A JP 2003546875A JP 4370168 B2 JP4370168 B2 JP 4370168B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- carnitine
- propionyl
- peyronie
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title claims abstract description 60
- 208000020758 Peyronie disease Diseases 0.000 title claims abstract description 57
- 208000004362 Penile Induration Diseases 0.000 title claims abstract description 56
- 238000011282 treatment Methods 0.000 title claims abstract description 56
- 150000003839 salts Chemical class 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960001722 verapamil Drugs 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 11
- 238000001990 intravenous administration Methods 0.000 claims abstract description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 46
- 229960001603 tamoxifen Drugs 0.000 claims description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 7
- 229960005294 triamcinolone Drugs 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 4
- 229960003459 allopurinol Drugs 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 235000019149 tocopherols Nutrition 0.000 claims description 4
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940057199 potassium aminobenzoate Drugs 0.000 claims description 3
- VLSHYHUKASKGPF-UHFFFAOYSA-M potassium;2-aminobenzoate Chemical compound [K+].NC1=CC=CC=C1C([O-])=O VLSHYHUKASKGPF-UHFFFAOYSA-M 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000001684 chronic effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 10
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 8
- 230000005750 disease progression Effects 0.000 description 8
- 238000009213 extracorporeal shockwave therapy Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003899 penis Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000009552 doppler ultrasonography Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- -1 colchicines Substances 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- KTFMPDDJYRFWQE-DDWIOCJRSA-N (3r)-3-propanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride Chemical compound [Cl-].CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C KTFMPDDJYRFWQE-DDWIOCJRSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- WCBVOPMSONYWEB-UHFFFAOYSA-N 2-aminoacetyl chloride Chemical compound NCC(Cl)=O WCBVOPMSONYWEB-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000404883 Pisa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229940095060 magnesium tartrate Drugs 0.000 description 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 description 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 description 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
このたび、プロピオニルL−カルニチンがアセチルL−カルニチンよりも大幅にペイロニー病の治療に有効であることが判明した。
本明細書に記載する本発明によると、プロピオニルL−カルニチンは、分子内塩の形態でも(この場合それ自体で医薬上許容される)、医薬上許容される酸との塩の形態でも使用することができる。
実施例は限られた患者数に基づくものであるため、結果の分析は疾患の基本的特徴についてのみ行った。即ち、該特徴とはプラーク面積(mm2で表示)(動的カラードップラー超音波検査手段によって測定した)および20μgのプロスタグランジンE1の空洞内注射によって誘発される人工的に勃起させた陰茎の屈曲である。
慢性段階の、陰茎の柔軟性が硬化した(ペイロニー病)40名の対象(平均年齢52歳、44−61歳の範囲)をランダムに各20名の患者の2群に分けた。第1群は、静脈内プロピオニルL−カルニチン300x2mg/日、3ヶ月間、の治療を受け、第2群は、経口タモキシフェン20x2mg/日の治療を受けた。測定した変数は、動的カラードップラー超音波検査手段によるプラーク面積および陰茎の屈曲であり、これは1群あたり16名の患者にみられた。静脈内プロピオニルL−カルニチンはタモキシフェンと比べて有意に大きい程度でプラーク面積及び人工的に勃起させた陰茎の屈曲を減少させるということが判明した。プラーク内ベラパミルはこれらの患者には用いなかった。
初期慢性段階の、陰茎の柔軟性が硬化した30名の対象(平均年齢50歳、42−63歳の範囲)をランダムに各15名の患者の2群に分けた。第1群は、筋肉内プロピオニルL−カルニチン、300x2mg/日、3ヶ月の治療を受け、第2群は、経口タモキシフェン、20x2mg/日の治療を受けた。測定した変数は、プラーク面積(すべての対象について)および陰茎の屈曲であり、後者は群あたり12名の対象にみられた。筋肉内プロピオニルL−カルニチンが、プラーク面積と人工的に勃起させた陰茎の屈曲をタモキシフェンと比較して有意に大きい程度に減少させるということが判明した。プラーク内ベラパミルはこれらの患者においては用いなかった。
この場合、試験集団は慢性段階の、陰茎の柔軟性が硬化しており、プラーク内ベラパミルでは治療できない不耐性を示す34名の患者から成るものであった(平均年齢50歳、44−63歳の範囲)。
無作為二重盲検プロトコールにしたがって調査を行った。
全部で合計60名の進行型ペイロニー病患者について調査し(平均年齢59歳、42−64歳の範囲)、ランダムに各30名の2群に分けた。疾患は、問診、理学的検査、薬剤誘発勃起、勃起した陰茎の写真、陰茎空洞動脈の基底および動的カラードップラー超音波検査、および「国際勃起スコア(”International Index of Erectile Function”)」(I.I.E.F. 15)質問表(Rosen R.C.、et al.: Urology 49: 822-830、1997)を用いることによって診断および調査した。患者に10回の10mgのベラパミルのプラーク内浸潤(1週間に1回の浸潤)を施した(Levine L.A.: J. Urol. 158: 1395-1399、1997)。第1群には、プロピオニルL−カルニチン1x2g/日を3ヶ月与え、第2群には、タモキシフェン20x2mg/日を3ヶ月与えた。データは治療の6ヶ月後に収集し、最初に行った問診と症候の調査を繰り返した。
前後比較予測計画によって調査を行った。この最後の群の対象に関しては、すでに受けた治療が非常に多数であるため、ケースコントロール計画を行うのは不可能であることが判明した。
疼痛、疾患の進行、手術の必要性および副作用に関するデータを治療前と治療の6ヶ月後にカイ二乗検定を用いて比較した。プラーク面積、陰茎の屈曲、I.I.E.F.15スコア、PSV、EDVおよびRIの差を、群間および治療の6ヶ月後に進行型ペイロニー病の場合、変動の2x2因子分析により、または、治療に耐性のペイロニー病患者においては乱塊(1患者=1塊)の変動分析により算出し、分析に影響する可能性のある個体変動を確認した。RIデータを角変換にかけ[sin−1(p/100)]、他のすべての場合には生データを用いた(Armitage P.: Statistical Methods in Medical Research. London: Blackwell Scientific Publications 1971)。
第1群の29名の患者(96.7%)は疼痛の減少を示し、1名の患者のみ(3.3%)についてはそのような減少は示されなかった;全く同じ結果が第2群において得られた(カイ二乗=0、P有意差なし)。
15名のうち9名の患者では、プラーク内ベラパミルおよび経口プロピオニルL−カルニチン投与前に疼痛があった;この治療後15名のうち1名の患者のみに疼痛があった(カイ二乗=7.35、P<0.01)。ベラパミルとプロピオニルL−カルニチンの組み合わせは、陰茎の屈曲(表9)およびプラーク面積(表10)を有意に減少させ、I.I.E.F.15スコア(表11)を有意に増加させることが判明した。ベラパミルとプロピオニルL−カルニチンの右と左の空洞動脈に対する効果をそれぞれ表12と13に示す。この薬剤の組み合わせは、EDVを有意に減少させ、RIを増加させることができると判明したが、PSVに対しては効果はなかった。3名の患者は手術を必要とし、1名の患者では疾患の進行がみられた。
Claims (5)
- プロピオニルL−カルニチンまたはその医薬上許容される塩の1つを、タモキシフェンおよびトリアムシノロンからなる群から選択される有効成分と組み合わせて含む、進行段階のペイロニー病の治療のための医薬組成物。
- さらに1以上の媒体および/または賦形剤を含む、請求項1の医薬組成物。
- プロピオニルL−カルニチンまたはその医薬上許容される塩の1つと、ペイロニー病の治療に有用なタモキシフェンおよびトリアムシノロンからなる群から選択される有効成分とが、共使用されるように製剤されている請求項1または2の医薬組成物、ここで共使用とは以下のいずれかを意味する;
プロピオニルL−カルニチンまたはその医薬上許容される塩の1つと、ペイロニー病の治療に有用なタモキシフェンおよびトリアムシノロンからなる群から選択される有効成分との同時または逐次投与; または
プロピオニルL−カルニチンまたはその医薬上許容される塩の1つと、ペイロニー病の治療に有用なタモキシフェンおよびトリアムシノロンからなる群から選択される有効成分とを混合物として含む組成物の投与。 - 進行段階のペイロニー病の治療のためのプロピオニルL−カルニチンまたはその医薬上許容される塩の1つを含む医薬組成物であって、経口、筋肉内または静脈内投与される医薬組成物。
- プロピオニルL−カルニチンまたはその医薬上許容される塩の1つを、トコフェロール類、ビタミンE、アロプリノール、アミノ安息香酸カリウム、タモキシフェン、トリアムシノロンまたはベラパミルと組み合わせて含む、進行段階のペイロニー病の治療のための、経口、筋肉内または静脈内投与のための医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001RM000695A ITRM20010695A1 (it) | 2001-11-26 | 2001-11-26 | Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del |
PCT/IT2002/000745 WO2003045373A1 (en) | 2001-11-26 | 2002-11-26 | Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005511638A JP2005511638A (ja) | 2005-04-28 |
JP2005511638A5 JP2005511638A5 (ja) | 2006-01-26 |
JP4370168B2 true JP4370168B2 (ja) | 2009-11-25 |
Family
ID=11455896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003546875A Expired - Fee Related JP4370168B2 (ja) | 2001-11-26 | 2002-11-26 | プロピオニルl−カルニチンまたはその医薬上許容される塩の1つのペイロニー病の治療用医薬の調製のための使用 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050038044A1 (ja) |
EP (1) | EP1448184B1 (ja) |
JP (1) | JP4370168B2 (ja) |
KR (1) | KR100923139B1 (ja) |
AT (1) | ATE323481T1 (ja) |
AU (1) | AU2002358991A1 (ja) |
CA (1) | CA2466135C (ja) |
CY (1) | CY1105347T1 (ja) |
DE (1) | DE60210804T2 (ja) |
DK (1) | DK1448184T3 (ja) |
ES (1) | ES2261772T3 (ja) |
HU (1) | HUP0402118A3 (ja) |
IT (1) | ITRM20010695A1 (ja) |
MX (1) | MXPA04004900A (ja) |
PL (1) | PL209317B1 (ja) |
PT (1) | PT1448184E (ja) |
WO (1) | WO2003045373A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2658307C2 (de) * | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO1983001782A1 (en) * | 1981-11-18 | 1983-05-26 | Merk, Werner | Fat refining |
US5038633A (en) * | 1989-09-28 | 1991-08-13 | Kabushiki Kaisha Kobe Seiko Sho | Transmission for mini shovel car |
IT1283967B1 (it) * | 1996-03-29 | 1998-05-07 | Sigma Tau Ind Farmaceuti | Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
IT1290600B1 (it) * | 1997-04-30 | 1998-12-10 | Sigma Tau Ind Farmaceuti | Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato |
IT1302858B1 (it) * | 1998-11-11 | 2000-10-10 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale. |
-
2001
- 2001-11-26 IT IT2001RM000695A patent/ITRM20010695A1/it unknown
-
2002
- 2002-11-26 WO PCT/IT2002/000745 patent/WO2003045373A1/en active IP Right Grant
- 2002-11-26 DK DK02793337T patent/DK1448184T3/da active
- 2002-11-26 EP EP02793337A patent/EP1448184B1/en not_active Expired - Lifetime
- 2002-11-26 MX MXPA04004900A patent/MXPA04004900A/es active IP Right Grant
- 2002-11-26 PT PT02793337T patent/PT1448184E/pt unknown
- 2002-11-26 JP JP2003546875A patent/JP4370168B2/ja not_active Expired - Fee Related
- 2002-11-26 PL PL371012A patent/PL209317B1/pl unknown
- 2002-11-26 ES ES02793337T patent/ES2261772T3/es not_active Expired - Lifetime
- 2002-11-26 US US10/496,659 patent/US20050038044A1/en not_active Abandoned
- 2002-11-26 CA CA2466135A patent/CA2466135C/en not_active Expired - Fee Related
- 2002-11-26 AT AT02793337T patent/ATE323481T1/de active
- 2002-11-26 AU AU2002358991A patent/AU2002358991A1/en not_active Abandoned
- 2002-11-26 HU HU0402118A patent/HUP0402118A3/hu unknown
- 2002-11-26 DE DE60210804T patent/DE60210804T2/de not_active Expired - Lifetime
- 2002-11-26 KR KR1020047007881A patent/KR100923139B1/ko not_active IP Right Cessation
-
2006
- 2006-05-30 CY CY20061100685T patent/CY1105347T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1448184B1 (en) | 2006-04-19 |
WO2003045373A1 (en) | 2003-06-05 |
CY1105347T1 (el) | 2010-03-03 |
HUP0402118A2 (hu) | 2005-02-28 |
DE60210804D1 (de) | 2006-05-24 |
AU2002358991A1 (en) | 2003-06-10 |
PL371012A1 (en) | 2005-06-13 |
CA2466135C (en) | 2011-05-31 |
HUP0402118A3 (en) | 2012-09-28 |
KR20040058316A (ko) | 2004-07-03 |
US20050038044A1 (en) | 2005-02-17 |
PL209317B1 (pl) | 2011-08-31 |
DK1448184T3 (da) | 2006-08-21 |
ATE323481T1 (de) | 2006-05-15 |
CA2466135A1 (en) | 2003-06-05 |
JP2005511638A (ja) | 2005-04-28 |
PT1448184E (pt) | 2006-07-31 |
EP1448184A1 (en) | 2004-08-25 |
DE60210804T2 (de) | 2006-10-19 |
ITRM20010695A0 (it) | 2001-11-26 |
KR100923139B1 (ko) | 2009-10-23 |
MXPA04004900A (es) | 2004-08-02 |
ITRM20010695A1 (it) | 2003-05-26 |
ES2261772T3 (es) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11234954B2 (en) | Low-dose doxepin for treatment of sleep disorders in elderly patients | |
JP2010525078A5 (ja) | ||
KR20070007887A (ko) | 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도 | |
JP2002541097A (ja) | 線維筋痛症及び関連症状の治療におけるフルピルチン | |
WO2002022128A1 (en) | A method of local anesthesia and analgesia | |
JP2003531171A (ja) | 高脂血症関連疾患に対する組成物および治療 | |
US7291625B2 (en) | Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation | |
EP2147671A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
WO2024078507A1 (zh) | 麦角甾醇在制备防治胃溃疡药物中的应用 | |
JP4370168B2 (ja) | プロピオニルl−カルニチンまたはその医薬上許容される塩の1つのペイロニー病の治療用医薬の調製のための使用 | |
JP2004536076A (ja) | P−gpインヒビターおよび抗癲癇薬を含んでなる組合せ剤 | |
JP4370169B2 (ja) | 勃起障害の治療のためのアルカノイルl−カルニチンの使用 | |
JP7344422B2 (ja) | 糖尿病予防・治療用の医薬品組成物及びその用途 | |
JP2002515035A (ja) | アミノステロール化合物の治療学的使用 | |
US7485642B2 (en) | Method for treating septic shock | |
Palmer et al. | Triethanolamine Trinitrate—Clinical Trial | |
RU2106877C1 (ru) | Способ лечения идиопатического дерматомиозита | |
CN117159518A (zh) | 一种大黄素在制备预防或治疗动脉粥样硬化药物组合物中的应用 | |
JPS5920221A (ja) | レイノ−症状の改善・治療剤 | |
Aristizábal Linares et al. | Effectiveness of Naltrexone in the Treatment of Severe Pruritus | |
DE102004040630A1 (de) | Kombinationstherapie mit Procain | |
WO2011041595A1 (en) | Methods and compositions for treatment of raynaud's phenomenon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051125 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090727 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090818 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090831 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120904 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130904 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |